查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541700

2024-2032 年替米沙坦市場報告（按適應症（高血壓、降低心血管風險）、配銷通路（醫院藥房、藥局和零售藥房、網路商店）和地區）

Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球替米沙坦市場規模達37億美元。

替米沙坦是一種非胜肽類血管張力素受體阻斷劑（ARB），用作治療高血壓和心血管疾病的處方藥。它通常以片劑和口服油懸浮液形式提供，並與其他藥物一起服用以增強其功效。它具有抗高血壓特性並抑制體內醛固酮的產生，從而減少鈉和水的吸收，從而降低血壓。替米沙坦還可以放鬆血管並促進腎功能。然而，它可能會引起各種副作用，例如頭暈、頭暈、咳嗽和鼻竇疼痛。

替米沙坦市場趨勢：

全球製藥業的顯著成長是創造積極市場前景的關鍵因素之一。此外，高血壓、糖尿病和各種腎臟相關疾病的盛行率不斷上升，也推動了市場的成長。替米沙坦已被證明可以有效修改胰島素敏感性基因以及調節葡萄糖和脂質代謝，有助於治療慢性糖尿病腎病變和久坐生活方式引起的其他疾病。藥廠也推出替米沙坦藥物的學名藥，為高血壓和心血管疾病提供經濟有效的治療。此外，藥品製造商正在大力投資用於治療糖尿病腎病變的先進替米沙坦藥物的研發（R＆D），這也促進了市場的成長。其他因素，包括老年人口的增加以及醫療基礎設施的顯著改善，預計將進一步推動市場。

本報告回答的關鍵問題：

  • 迄今為止，全球替米沙坦市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球替米沙坦市場有何影響？
  • 主要區域市場有哪些？
  • 根據指示，市場的細分是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球替米沙坦市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球替米沙坦市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依跡象

  • 高血壓
    • 市場趨勢
    • 市場預測
  • 降低心血管風險
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 藥局和零售藥局
    • 市場趨勢
    • 市場預測
  • 網路商店
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 9 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Aurobindo Pharma USA
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • Hikma Pharmaceuticals plc
    • Jubilant Cadista Pharmaceutical
    • Sanofi SA
    • Solco Healthcare (Prinston Pharmaceutical Inc.)
    • Torrent Pharmaceuticals Ltd
Product Code: SR112024A4074

The global telmisartan market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032.

Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.

Telmisartan Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and distribution channel.

Breakup by Indication:

Hypertension

Cardiovascular Risk Reduction

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.

Key Questions Answered in This Report:

  • How has the global telmisartan market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global telmisartan market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global telmisartan market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Telmisartan Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Hypertension
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiovascular Risk Reduction
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Drug Stores and Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurobindo Pharma USA
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 Boehringer Ingelheim International GmbH
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals plc
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Jubilant Cadista Pharmaceutical
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Sanofi S.A.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Torrent Pharmaceuticals Ltd
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Telmisartan Market: Major Drivers and Challenges
  • Figure 2: Global: Telmisartan Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Telmisartan Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Telmisartan Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Telmisartan Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Telmisartan Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Telmisartan (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Telmisartan (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Telmisartan (Cardiovascular Risk Reduction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Telmisartan (Cardiovascular Risk Reduction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Telmisartan (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Telmisartan (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Telmisartan (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Telmisartan (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: North America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: North America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: United States: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: United States: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Canada: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Canada: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Asia-Pacific: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Asia-Pacific: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: China: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: China: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Japan: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Japan: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: India: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: India: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: South Korea: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: South Korea: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Australia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Australia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Indonesia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Indonesia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Europe: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Europe: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Germany: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Germany: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: France: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: France: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United Kingdom: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United Kingdom: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Italy: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Italy: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Spain: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Spain: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Russia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Russia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Latin America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Latin America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Brazil: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Brazil: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Mexico: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Mexico: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Middle East and Africa: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Middle East and Africa: Telmisartan Market: Breakup by Country (in %), 2023
  • Figure 65: Middle East and Africa: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Global: Telmisartan Industry: SWOT Analysis
  • Figure 67: Global: Telmisartan Industry: Value Chain Analysis
  • Figure 68: Global: Telmisartan Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Telmisartan Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Telmisartan Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Telmisartan Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Telmisartan Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Telmisartan Market: Competitive Structure
  • Table 6: Global: Telmisartan Market: Key Players